Toll Free: 1-888-928-9744

Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016

Published: Nov 30, 1999 | Pages: 54 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Global Markets Direct's, ‘Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016', provides in depth analysis on Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2)
- The report reviews Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Overview 7 Therapeutics Development 8 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Stage of Development 8 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Therapy Area 9 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Indication 10 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Companies 13 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Products under Development by Universities/Institutes 15 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 21 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Companies Involved in Therapeutics Development 22 Addex Therapeutics Ltd 22 Domain Therapeutics SA 23 Eli Lilly and Company 24 Johnson & Johnson 25 Merck & Co., Inc. 26 Taisho Pharmaceutical Holdings Co., Ltd. 27 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Drug Profiles 28 ADX-92639 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 JNJ-40411813 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 LSN-2535717 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 LY-2607540 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 MGS-0028 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules to Antagonize mGluR2 for Parkinson's Disease - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Dormant Projects 39 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Discontinued Products 42 Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Featured News & Press Releases 43 Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 43 Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 43 Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 44 Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 44 Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 45 Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 47 Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 48 Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 48 Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 49 Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 50 Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 51 Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 51 Jan 17, 2005: Addex Pharmaceuticals Enters Into Collaboration With Ortho-McNeil Pharmaceutical To Develop Novel Treatments For Anxiety, Depression, Schizophrenia And Alzheimer's Disease 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Addex Therapeutics Ltd, H1 2016 22 Pipeline by Domain Therapeutics SA, H1 2016 23 Pipeline by Eli Lilly and Company, H1 2016 24 Pipeline by Johnson & Johnson, H1 2016 25 Pipeline by Merck & Co., Inc., H1 2016 26 Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 27 Dormant Projects, H1 2016 39 Dormant Projects (Contd..1), H1 2016 40 Dormant Projects (Contd..2), H1 2016 41 Discontinued Products, H1 2016 42


List of Figures
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 21

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify